Compass Therapeutics Sees Major Institutional Investment Boost

Suvretta Capital Management LLC significantly increased its stake in the biotech company.

Mar. 14, 2026 at 11:22am

Got story updates? Submit your updates here. ›

Suvretta Capital Management LLC, an institutional investor, boosted its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 97.2% in the third quarter. The firm now owns approximately 10.2% of Compass Therapeutics, a clinical-stage biotech company focused on developing novel immuno-oncology therapies.

Why it matters

This significant increase in institutional ownership signals growing investor confidence in Compass Therapeutics and its pipeline of innovative cancer immunotherapies. Institutional investors like Suvretta often conduct extensive due diligence before making large investments, so this move suggests they see strong potential in the company's future.

The details

According to the filing, Suvretta Capital Management increased its position in Compass Therapeutics from around 7.1 million shares to over 14.1 million shares in the third quarter of 2025. This represents an increase of 97.2% and makes Suvretta the largest institutional shareholder, owning approximately 10.2% of the company's outstanding stock.

  • Suvretta Capital Management increased its stake in Compass Therapeutics in the third quarter of 2025.

The players

Suvretta Capital Management LLC

An institutional investment firm that significantly increased its stake in Compass Therapeutics, now owning approximately 10.2% of the company's outstanding stock.

Compass Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing novel immuno-oncology therapies, including bispecific antibodies and CD47-SIRPα pathway modulators.

Got photos? Submit your photos here. ›

The takeaway

Compass Therapeutics' ability to attract major institutional investment suggests the company's pipeline and strategy are resonating with sophisticated investors. This vote of confidence could help the biotech firm advance its innovative cancer immunotherapies through clinical development and towards potential regulatory approval.